3-环己基-2-(2-羟苯基)-1H-吲哚-6-羧酸甲酯 | 863578-50-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3-环己基-2-(2-羟苯基)-1H-吲哚-6-羧酸甲酯
• 中文别名: 3-环己基-2-(2-羟基苯基)-1H-吲哚-6-羧酸甲酯
• 英文名称: 3-cyclohexyl-2-(2-hydroxy-phenyl)-1H-indole-6-carboxylic acid methyl ester
• 英文别名: 3-cyclohexyl-2-(2-hydroxyphenyl)-1H-indole-6-carboxylic acid methyl ester；methyl 3-cyclohexyl-2-(2-hydroxyphenyl)-1H-indole-6-carboxylate
• CAS: 863578-50-1
• 化学式: C₂₂H₂₃NO₃
• 分子量: 349.43
• InChiKey: YYRKDUZWMBHTAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  62.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-环己基-2-(2-羟苯基)-1H-吲哚-6-羧酸甲酯 在 吡啶 、 palladium on activated charcoal 、 potassium tert-butylate 、 sodium acetate 、 三乙酰氧基硼氢化钠 、 caesium carbonate 、 二甲基亚砜 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 甲醇 、 DCE 、 N,N-二甲基乙酰胺 为溶剂， 反应 5.0h， 生成 methyl (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl)-amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylate
  参考文献：
  名称：

  Mitsunobu Inversion of a Secondary Alcohol with Diphenylphosphoryl azide. Application to the Enantioselective Multikilogram Synthesis of a HCV Polymerase Inhibitor

  摘要：

  The development of a practical synthesis of the hepatitis C virus polymerase inhibitor 1 was necessary to support preclinical safety and human clinical studies. Significant challenges face the process chemist in developing a route to 1 that is amenable to multikilogram operation. In particular, an efficient construction of the eight-membered dihydroindolobenzoxazocine ring and enantioselective synthesis of the secondary amine stereocenter are required. This article describes our process development of a Mitsunobu protocol to achieve the latter goal which uses diphenylphosphoryl azide at ambient temperature to invert a scalemic secondary alcohol, The hazard evaluation performed to establish the safety of this protocol and allow pilot-plant introduction at > 8.0 kg scale is discussed. Overall, an enantioselective synthesis of 1 by way of seven isolated intermediates in 32% overall yield was developed from commercially available materials. This allowed us to prepare over 3 kg of the targeted drug candidate.

  DOI：

  10.1021/op200002u
• 作为产物：
  描述：

  环己基乙酸 在 甲烷磺酸 、 palladium on carbon 、 氢溴酸 、 potassium carbonate 、 溶剂黄146 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 、 正庚烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 5.0~75.0 ℃ 、230.0 kPa 条件下， 反应 3.17h， 生成 3-环己基-2-(2-羟苯基)-1H-吲哚-6-羧酸甲酯
  参考文献：
  名称：

  An Efficient Process for the Large-Scale Synthesis of a 2,3,6-Trisubstituted Indole

  摘要：

  The efficient synthesis of a key trisubstituted indole intermediate 1 is described. The synthetic route required the use of an aryl Grignard reagent which was not commercially available, and the large-scale formation of this fragment and the thermal evaluation for this step is presented. The key step in the sequence was a Truce-Smiles rearrangement to provide an advanced ketone intermediate which, upon reduction, cyclized to the desired indole 1. Design of experiment (DoE) optimization of this reduction is also presented. In total >50 kg of target indole 1 were synthesized in 55% overall yield over five steps using this new route.

  DOI：

  10.1021/op300303p

文献信息

• [EN] MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS<br/>[FR] DÉRIVÉS MACROCYCLIQUES D'INDOLE POUR LE TRAITEMENT DES INFECTIONS D'HÉPATITE C
  申请人：ANGELETTI P IST RICHERCHE BIO

  公开号：WO2009010783A1

  公开（公告）日：2009-01-22

  A class of macrocyclic compounds of formula (I), wherein R7, R9, B, F, M, Q, W, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such 5 macrocyclic compounds for treating or preventing HCV infection.

  提供一类宏环化合物的化学式(I)，其中R7、R9、B、F、M、Q、W、Y和Z的定义如下，这些化合物可用作病毒蛋白酶抑制剂，特别是对乙型肝炎病毒（HCV）NS3蛋白酶的抑制剂。还提供了合成和使用这些5种宏环化合物的方法，用于治疗或预防HCV感染。
• Inhibitors of HCV replication
  申请人：Hudyma W. Thomas

  公开号：US20060046983A1

  公开（公告）日：2006-03-02

  Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds.

  化合物I的吲哚类化合物已被描述。这些化合物对丙型肝炎病毒（HCV）具有活性，并可用于治疗感染HCV的人。还描述了包含这些化合物的不同形式和组成，以及制备这些化合物的方法。
• Discovery of Conformationally Constrained Tetracyclic Compounds as Potent Hepatitis C Virus NS5B RNA Polymerase Inhibitors
  作者：Kazutaka Ikegashira、Takahiro Oka、Shintaro Hirashima、Satoru Noji、Hiroshi Yamanaka、Yoshinori Hara、Tsuyoshi Adachi、Jun-Ichiro Tsuruha、Satoki Doi、Yasunori Hase、Toru Noguchi、Izuru Ando、Naoki Ogura、Satoru Ikeda、Hiromasa Hashimoto

  DOI：10.1021/jm0610245

  日期：2006.11.30

  We report a new series of hepatitis C virus NS5B RNA polymerase inhibitors containing a conformationally constrained tetracyclic scaffold. SAR studies led to the identification of 6,7-dihydro-5H-benzo[5,6][1,4]diazepino[7,1-a]indoles (19 and 20) bearing a basic pendent group with high biochemical and cellular potencies. These compounds displayed a very small shift in cellular potency when the replicon

  我们报告了一系列新的丙型肝炎病毒 NS5B RNA 聚合酶抑制剂，其中包含构象受限的四环支架。SAR 研究导致鉴定 6,7-二氢-5H-苯并[5,6][1,4]二氮杂[7,1-a]吲哚（19 和 20）具有高生化和细胞效力。当在人血清白蛋白存在下进行复制子测定时，这些化合物在细胞效力方面表现出非常小的变化。
• Development of a Scalable Chiral Synthesis of MK-3281, an Inhibitor of the Hepatitis C Virus NS5B Polymerase
  作者：Stefania Colarusso、Jörg Habermann、Immacolata Conte、Marcello Di Filippo、Caterina Ercolani、Angela Mackay、Maria Palumbi、Maria del Rosario Rico Ferreira、Ian Stansfield、Simone Zaramella、Frank Narjes

  DOI：10.1055/s-0030-1260790

  日期：2011.7

  The development of a scalable chiral synthesis for the HCV NS5B inhibitor MK-3281 is being reported. Several alternative routes were explored and are being described.

  本报告介绍了 HCV NS5B 抑制剂 MK-3281 的可扩展手性合成方法。对几种替代路线进行了探索，现予以介绍。
• Tetracyclic indole derivatives as antiviral agents
  申请人：Conte Immacolata

  公开号：US20060100262A1

  公开（公告）日：2006-05-11

  The present invention relates to tetracyclic indole compounds of formula (I): wherein R 1 , R 2 , A, Ar, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.

  本发明涉及公式（I）的四环吲哚化合物，其中R1、R2、A、Ar、W、X、Y和Z的定义如下，以及其药学上可接受的盐，包括它们的药物组成物，并用于治疗或预防丙型肝炎病毒感染的用途。